logo
Company halts secret tracking campaign following wave of backlash: 'They were unable to win'

Company halts secret tracking campaign following wave of backlash: 'They were unable to win'

Yahoo07-03-2025

A U.S. firm spent years secretly tracking scientists and activists who challenge the pesticide industry — using taxpayer money to do it. Now, after public backlash, the company says it's shutting down. But is the damage already done?
For years, v-Fluence, a Missouri-based firm with ties to agrochemical giants, ran a private online portal where it stored detailed profiles of over 500 critics of pesticides and genetically modified crops, reported The Guardian. This included personal details like home addresses, phone numbers, and even information about family members. The portal's audience included over 1,000 industry executives, lobbyists, regulatory staffers, and academics, all with a vested interest in silencing the opposition.
The operation was partially funded by U.S. taxpayer money, with contracts funneled through organizations promoting industrial agriculture abroad. After an investigation led by The Guardian, The New Lede, Le Monde, and other international media partners, the exposure triggered widespread condemnation and legal threats. v-Fluence has since said it has eliminated the profiling and laid off staff, though critics say the harm cannot be undone.
"Those of us who were profiled still do not know who accessed the information and how it was used," said London research professor Michael Antoniou, who was profiled on the portal. "The fact that v-Fluence and the industries it serves resorted to these underhand methods shows that they were unable to win on the level of the science."
Beyond the obvious privacy violations, v-Fluence's actions highlight how corporations attempt to manipulate public discourse around pesticides and GMOs. By tracking and discrediting critics, they aim to suppress legitimate concerns over chemical safety, environmental impact, and public health.
This is especially alarming given that v-Fluence worked with Syngenta, a pesticide company facing thousands of lawsuits over its herbicide paraquat, which has been linked to Parkinson's disease.
Wendy Wagner, a University of Texas law professor and expert on toxic substance regulation, noted, "I'm quite familiar with corporate harassment of scientists who produce unwelcome research. ... But I have not encountered the use of larger databases that track personal details of numerous critics of a corporation [including independent scientists and journalists]. It is hard to see the relevance of personal details short of use as harassment."
If industry-backed operations like this continue, scientists and activists could be discouraged from speaking out, leading to weaker regulations and more unchecked corporate influence over food and environmental policies.
After The Guardian and its media partners exposed the operation, v-Fluence hired a law firm to see if it violated EU data privacy laws. The review found the company wasn't legally bound by the General Data Protection Regulation (GDPR) but advised it to follow the rules anyway, just in case. As a result, v-Fluence removed the profiles but plans to continue its "stakeholder research" with updated guidelines.
Do you think we should deal with air pollution by burying things underground?
Sounds great
No way
Only for certain waste
I'm not sure
Click your choice to see results and speak your mind.
The revelations have sparked growing calls for stricter oversight of corporate lobbying and surveillance, with advocates pushing for the U.S. government to stop funding organizations that undermine scientific integrity. Groups like Greenpeace, Food & Water Watch, and the Center for Food Safety are working to expose industry misconduct and push for stronger regulations. Staying informed and speaking out, especially on social media, can help keep these tactics in check.
Holding corporations accountable isn't just about privacy; it's about protecting public health and the environment.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

Yahoo

timean hour ago

  • Yahoo

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Simple tool could detect Parkinson's disease early — it was 96% accurate in experiments
Simple tool could detect Parkinson's disease early — it was 96% accurate in experiments

New York Post

time2 hours ago

  • New York Post

Simple tool could detect Parkinson's disease early — it was 96% accurate in experiments

This pen truly is mightier than the sword. A team of researchers at UCLA has developed a high-tech diagnostic pen that can detect signs of Parkinson's disease with over 96% accuracy, offering a low-cost way to identify the neurodegenerative disorder far earlier than now. A pilot study in the journal Nature Chemical Engineering unveiled the device, which looks much like a regular pen. 3 A patient with PD using the diagnostic pen for a writing task. Nature Chemical Engineering It's able pick up on subtle motor dysfunctions before they're visible to the naked eye, all by analyzing how people write. So, how does this futuristic fountain pen work? The tip is made of a flexible silicone material infused with magnetic particles, and it writes using a special ferrofluid ink that contains nanomagnets. As someone writes, pressure from the hand deforms the tip, causing changes in magnetic fields that produce electrical signals — like a Morse code of motor function. Those signals are then analyzed to detect the difference between healthy and Parkinson's-affected motor patterns. In tests with 16 participants — including 3 with Parkinson's — the system nailed the diagnosis with 96.22% accuracy. Even more impressive? The pen worked whether people wrote on paper or in the air, meaning it doesn't even require a surface. 3 Nature Chemical Engineering Today, Parkinson's is largely diagnosed based on observations, which are subjective, or by biomarker-based imaging, which can be expensive. This diagnostic pen is portable, inexpensive and doesn't rely on a neurologist to interpret results, making it a promising option for remote screenings, home use or even telehealth checkups. 'Our development of the diagnostic pen represents a low-cost, widely disseminable and reliable technology with the potential to improve PD diagnostics across large populations and resource-limited areas,' the researchers wrote. With further validation in a larger population, the device could be used not just for early diagnosis, but for ongoing symptom tracking and personalized treatment monitoring. 3 Today, Parkinson's is largely diagnosed based on observations, which are subjective, or by biomarker-based imaging, which can be expensive. highwaystarz – This is just the latest innovation aimed at tackling Parkinson's disease, which affects more than 10 million people worldwide and has no known cure. A recent study found that psilocybin — the psychedelic compound that gave 'magic mushrooms' their trippy reputation in the 1960s — showed serious promise for improving mood and motor function in people with Parkinson's disease. Tavapadon — a new drug that mimics dopamine by targeting certain receptors — has also shown promise in clinical trials by reducing motor fluctuations and maintaining symptom control with fewer side effects than traditional therapies. Produodopa — a continuous infusion therapy first administered in the UK — was approved by the US Food and Drug Administration last fall. Innovative approaches targeting the psychological aspects of the disease have been successful as well — with tandem cycling proving to be especially popular. Some New Yorkers even find relief by playing pingpong.

Missing El Paso woman found dead in vacant building in Missouri
Missing El Paso woman found dead in vacant building in Missouri

Yahoo

time4 hours ago

  • Yahoo

Missing El Paso woman found dead in vacant building in Missouri

An El Paso woman reported missing four months ago has been found dead inside a vacant building in Missouri, the Montgomery County Sheriff's Office stated. The body of the 37-year-old woman, whose name has not been released, was found on June 3 inside a vacant building in New Florence, Missouri, Montgomery County Sheriff Craig S. Allison said in a news release on Friday, June 6. Missing children in El Paso: 'I will always be looking:' El Paso teens featured on missing children billboards The cause of death had yet to be determined and an investigation continues. "Our thoughts and prayers are with the family and loved ones of the deceased during this very difficult time," the sheriff's office stated. New Florence is a tiny town of about 600 residents located along Interstate 70 about 75 miles west of St. Louis. On the evening of June 3, New Florence police responded to a 911 hang-up call and were directed to the bay area of a vacant building on Booneslick Road, where two people had found a body inside, the sheriff's office stated. The Montgomery County Sheriff's Office and the Missouri State Highway Patrol's Troop F Division of Drug and Crime Control are handling the investigation. Crime: Fort Bliss soldier arrested on animal cruelty charge in video of dog hanging off truck Anyone with information on the death investigation may call the Montgomery County Sheriff's Office at 573-564-3378 or the Missouri State Highway Patrol Division of Drug and Crime Control at 573-751-1000. Daniel Borunda may be reached at dborunda@ and @BorundaDaniel on X. This article originally appeared on El Paso Times: Missing El Paso woman found dead in vacant building in Missouri

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store